Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

Cannabis (Cannabis sativa L.) has a long history as a medicinal plant. This plant has been known and used since ancient times, and cannabis use demonstrates numerous therapeutic effects, including antispastic, analgesic, antiemetic, neuroprotective, and anti-inflammatory actions. Indeed, it is also effective against certain psychiatric diseases. Cannabinoid compounds, occurring in cannabis, produce their effects via interaction with the brain’s endocannabinoid system (ECS). The ECS, through the cannabinoid type 1 (CB1) and type 2 (CB2) receptors, is involved in many emotional functions and there are a wide variety of interactions between the CB receptors and many different neurotransmitters and neuromodulators in the central and peripheral nervous system. The pharmacological modulation of ECS functions could be useful for the treatment of various medical conditions. However, the knowledge on the potential mechanisms of cannabinoid activities still requires further enrichment. Thus, the aim of the Special Issue is to expand the current knowledge of the role of the ECS in the pathomechanisms of many mental and physical dysfunctions. This knowledge may in the future open up new possibilities for the development of cannabinoid-based therapies for many disorders. A step towards this of this project will be to bring together international experts to provide a comprehensive overview about this research field. Therefore, I invite you to participate with either an original article or a review focused on some aspects of the subject.

Dr. Marta Kruk-Słomka
Dr. Jolanta Orzelska-Górka
Dr. Ewa Kędzierska
Dr. Ewa Gibuła-Tarłowska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

endocannabinoid system
cannabinoid receptor ligands
medical marihuana
cannabinoid-based therapies

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

15 pages, 1681 KiB

Open AccessArticle

Systemic Chronic Treatment with Cannabidiol in Carioca High- and Low-Conditioned Freezing Rats in the Neuropathic Pain Model: Evaluation of Pain Sensitivity

by Carolina Macêdo-Souza, Silvia Soares Maisonnette, Jaime E. Hallak, José A. Crippa, Antônio W. Zuardi, J. Landeira-Fernandez and Christie Ramos Andrade Leite-Panissi

Pharmaceuticals 2023, 16(7), 1003; https://doi.org/10.3390/ph16071003 - 14 Jul 2023

Cited by 1 | Viewed by 1126

Abstract

Studies have shown high comorbidity of anxiety disorder and chronic pain; generalized anxiety disorder (GAD) and neuropathic pain are among these pathologies. Cannabidiol (CBD) has been considered a promising treatment for these conditions. This study investigated whether chronic systemic treatment with CBD alters pain in high- (CHF) and low-freezing (CLF) Carioca rats (GAD model) and control rats (CTL) submitted to chronic neuropathic pain. The rats were evaluated in the sensory aspects (von Frey, acetone, and hot plate tests) before the chronic constriction injury of the ischiatic nerve (CCI) or not (SHAM) and on days 13 and 23 after surgery. Chronic treatment with CBD (5 mg/kg daily) was used for ten days, starting the 14th day after surgery. The open field test on the 22nd also evaluated locomotion and anxiety-like behavior. CBD treatment had an anti-allodynic effect on the mechanical and thermal threshold in all lineages; however, these effects were lower in the CHF and CLF lineages. Considering emotional evaluation, we observed an anxiolytic effect in CTL+CCI and CHF+CCI after CBD treatment and increased mobility in CLF+SHAM rats. These results suggest that the CBD mechanical anti-allodynic and emotional effects can depend on anxiety level. Full article

(This article belongs to the Special Issue Therapeutic Potential for Cannabinoid and Its Receptor)

► Show Figures

Journal Menu

Journal Browser

Therapeutic Potential for Cannabinoid and Its Receptor

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI